Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FDNZ
- Development stage
- Preclinical
- Lead developer
- National Institute on Drug Abuse
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
FDNZ is a novel fluorinated nitazene analog developed by researchers at the National Institute on Drug Abuse (NIDA). It acts as a highly potent mu-opioid receptor (MOR) agonist with poor blood-brain barrier permeability, resulting in impaired brain penetrance. Preclinical studies in rodents demonstrate that FDNZ produces robust peripheral analgesic effects with weak reinforcing properties and a rapid extinction of self-administration behavior, suggesting a lower risk of abuse liability and respiratory depression compared to conventional centrally-penetrant MOR agonists.
- Other names
- 2-fluoroethyl-benzimidazole hydrochloride
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on FDNZ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FDNZ.